BioSpace News Archive

According to the current analysis of Reports and Data, the global Mycoplasma Testing market was valued at USD 609.39 Million in 2019 and is expected to reach USD 1.59 Billion by year 2027, at a CAGR of 12.6%.

According to the current analysis of Reports and Data, the global Viral Vector and Plasmid DNA manufacturing market is expected to reach USD 4.70 billion by the year 2028, with a CAGR of 23.8% during the forecast period.

Kala Pharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022.

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and subsidiary of Pace® Science and Technology Company, announced that it has acquired Meridian BioGroup.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

Relay Therapeutics, Inc. (Nasdaq: RLAY), today announced that a late breaking abstract of interim clinical data from the ReFocus trial for RLY-4008 has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held September 9-13, 2022.

Alpine Immune Sciences, Inc. announced that, in connection with the previously announced appointment of Andrew S. Sandler, M.D. as Chief Medical Officer, it has granted Dr. Sandler an option to purchase 160,000 shares of common stock.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17th Annual Wells Fargo Securities Healthcare Conference.

Nuance Pharma announces the Center for Drug Evaluation has approved its Investigational New Drug application supporting its pivotal clinical trial of Ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease in mainland China.

Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market